Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response
ChemMedChem · 2023
DOI: 10.1002/cmdc.202200673 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, 2023. Verfasst von Qian-Ting Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience, National Center for Nanoscience a…. Hauptthemen laut MEDLINE: Neoplasms, Cancer Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 104 Literaturangaben. Gefördert von: Strategic Priority Research Program of the Chinese Academy of Sciences.
Abstract (Originalsprache)
Many advances have been made recently in the field of cancer immunotherapy, particularly with the development of treatments such as immune checkpoint inhibitors and adoptive cellular immunotherapy. The efficacy of immunotherapy is limited, however, owing to high levels of tumor heterogeneity and the immunosuppressive environments of advanced malignant tumors. Therefore, therapeutic anticancer vaccines have gradually become powerful tools for inducing valid antitumor immune responses and regulating the immune microenvironment. Tumor vaccines loaded in nanocarriers have become an indispensable delivery platform for tumor treatment because of their enhanced stability, targeting capability, and high level of safety. Through a unique design, cancer nanovaccines activate innate immunity and tumor‐specific immunity simultaneously. For example, the design of cancer vaccines can incorporate strategies such as enhancing the stability and targeting of tumor antigens, combining effective adjuvants, cytokines, and immune microenvironment regulators, and promoting the maturation and cross‐presentation of antigen‐presenting cells (APCs). In this review, we discuss the design and preparation of nanovaccines for remodeling tumor antigen immunogenicity and regulating the immunosuppressive microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing, 100190, P. R. China.
- University of the Chinese Academy of Sciences (UCAS), Beijing, 100049, P. R. China.
ORCID-Profile: Qian-Ting Wang, Hao Wang
Förderung
- Strategic Priority Research Program of the Chinese Academy of Sciences
Zitieren
APA
Wang, Q. T., Liu, Y. X., Wang, J., & Wang, H. (2023). Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response. ChemMedChem. https://doi.org/10.1002/cmdc.202200673
Vancouver
Wang QT, Liu YX, Wang J, Wang H. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response. ChemMedChem. 2023. doi:10.1002/cmdc.202200673
BibTeX
@article{Wang2023,
author = {Wang, Qian-Ting and Liu, Yi-Xuan and Wang, Jie and Wang, Hao},
title = {Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response},
journal = {ChemMedChem},
year = {2023},
doi = {10.1002/cmdc.202200673}
}
EUVIMED